News & Events
Proteostasis is a drug discovery company addressing diseases caused by defects in protein folding, trafficking and clearance for orphan and neurodegenerative diseases, including Cystic Fibrosis (CF). Professor Jane Davies, from Imperial’s National Heart and Lung Institute, will join five other world leading experts on their CF clinical advisory board.
The panel will serve as a strategic resource for the upcoming selection and study of the Company’s leading compounds that double the activity of the drug combination ivacaftor/lumacaftor in the gold-standard test using Human Bronchial Epithelial cells (HBE cell assay). This drug combination has been shown to significantly improve lung function in sufferers with the most common CF mutation, F508del/F508del, and it is hoped that the compounds selected for further development can build on this.
Meenu Chhabra, President and Chief Executive Officer of Proteostasis Therapeutics said:
“The knowledge and experience that our inaugural clinical advisory board members bring to Proteostasis will be invaluable not only in the selection process of which of our proprietary PTI CFTR compounds should proceed to clinical development, but also in providing guidance on the design and conduct of the future clinical trials of selected drug candidates.”
World leading Cystic Fibrosis expertise
Professor Davies is Professor of Paediatric Respirology and Experimental Medicine at Imperial College London and an Honorary Consultant in Paediatric Respiratory Medicine at the Royal Brompton & Harefield NHS Foundation Trust. She is the site co-PI for the European CF Society Clinical Trials Network and leads their Lung Clearance Index Core facility. She has experience in clinical trial design for both investigator-initiated and pharma-sponsored studies and has advised companies in this area as a consultant through ICON on many occasions.
Professor Jane Davies comments:
“It is exciting to see so many pharmaceutical companies taking up the challenge of drug development in this area. I am delighted that companies such as Proteostasis are recognising the benefits of building relationships with clinicians and investigators in the CF field and of working collaboratively, from an early stage, towards optimal clinical trial design of novel drugs.”
Please click here for the Proteostasis press release.
For more information on consultancy in this area, please contact us.
Share post:
Latest news, insights and events
Groundbreaking analysis reveals a fully flexible energy system could cut the cost of reaching net zero by up to £16.7bn a year in 2050
Analysis led by the Carbon Trust and Prof Strbac and supported by Bryt Energy, EDF, Greater London Authority, IGEM, Kiwi Power, Low Carbon Contracts Company, SBM Offshore, SP Energy Networks, Statera Energy, Scottish and Southern Electricity Networks (SSEN), UK Power Networks and Western Power Distribution. read more
Imperial Consultants provides expertise for iconic company: BSI
The UK’s National Standards Body, BSI (British Standards Institution), has commissioned consultancy advice within data modelling expertise to look at improving smart city implementation. read more
Prof David Nethercot appointed as assessor to assist Grenfell Tower Inquiry Chairman
David Nethercot, Emeritus Professor of Civil Engineering, has been appointed by the Chairman of the Grenfell Tower Inquiry to assist him in considering technical issues relating to the design and construction of the building and its refurbishment. read more